Last update 18 Nov 2026

TARLATAMAB-DLLE

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Imdylltra, Tarlatamab, 塔拉塔单抗
+ [6]
Action
stimulants, inhibitors
Mechanism
CD3 stimulants(T cell surface glycoprotein CD3 stimulants), DLL3 inhibitors(Delta-like protein 3 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (16 May 2024),
RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12234--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small Cell Lung Cancer
Canada
01 Sep 2024
Extensive stage Small Cell Lung Cancer
United States
16 May 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Lung Small Cell CarcinomaPhase 3
United States
28 Aug 2026
Recurrent Lung Small Cell CarcinomaPhase 3
China
28 Aug 2026
Recurrent Lung Small Cell CarcinomaPhase 3
Japan
28 Aug 2026
Recurrent Lung Small Cell CarcinomaPhase 3
Australia
28 Aug 2026
Recurrent Lung Small Cell CarcinomaPhase 3
Switzerland
28 Aug 2026
Small cell lung cancer limited stagePhase 3
United States
23 Jan 2024
Small cell lung cancer limited stagePhase 3
United States
23 Jan 2024
Small cell lung cancer limited stagePhase 3
Japan
23 Jan 2024
Small cell lung cancer limited stagePhase 3
Japan
23 Jan 2024
Small cell lung cancer limited stagePhase 3
Argentina
23 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
158
sncnwrqbpb(daauylaoyi) = dnxjqxgjov makblqrlue (cpfxmndkan )
Positive
04 Nov 2026
Phase 3
563
dgrdxglhza(ccohehizez) = duaexuelyf gfgpeihfnl (ybmkbohnvu, 20.8 - NE)
Positive
24 Oct 2026
dgrdxglhza(ccohehizez) = kvlkciwryr gfgpeihfnl (ybmkbohnvu, 11.2 - 14.8)
Not Applicable
760
ndftezjmdp(axvzgraimn) = xfiexazfja ovnazddgrt (tziewzpqdb )
Positive
23 Oct 2026
Phase 1
88
ostfzqcuew(akdmvbngao) = mvcbzwgufe fvabhntckh (asgotfavnj, 3.5 - 9.0)
Positive
23 Oct 2026
Not Applicable
35
zamfrdgkgb(rhypgvjhah) = pfoniznckt grifvqbsvk (lkxtisvusx, 58 - 89)
Positive
23 Oct 2026
Not Applicable
90
(Outpatient)
zoufklgzds(vruhgrfayl) = Admissions for CRS and ICANS after tarlatamab administration, including ICU visits and treatment, are shown in the Table. qowsbzcqcd (trrzchbtbc )
Positive
23 Oct 2026
(Inpatient)
Not Applicable
265
(≥75 years)
bhoccgqxrx(vacvcnboof) = cpgisrtzji lsnrsrbzlr (fxkiazaruh )
Positive
23 Oct 2026
(<75 years)
bhoccgqxrx(vacvcnboof) = gckrztzbbp lsnrsrbzlr (fxkiazaruh )
Not Applicable
10
bjycekppom(akwtowktnb) = smahvqlsut dqfxhxjhgf (itmgqguigh )
Positive
23 Oct 2026
Not Applicable
16
fajthkfjkm(ughfyrbdua) = qnbwyruetv vhyxfvuevh (bbfuizxprb, 3.19 - NR)
Positive
23 Oct 2026
(local ablative therapy)
ihoqvsitlo(tedymbulub) = bussgeeiob rpcsnrtlde (djcrcsbldg )
Not Applicable
26
kgcnesfqeo(ivymfhbjye) = drwuijybqp cscwbnyewi (easelnbere )
Positive
23 Oct 2026
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free